I’m thrilled to see you! But I’d love even more for you to join the conversation at this blog’s new home at Wired:

http://www.wired.com/wiredscience/superbug

— Maryn

I give you: the Singing Doctors! (via damagedcare.com):

This is an addition for archival purposes of a post that originally appeared at Scienceblogs.

In the winter of 1999, I stood in an outpatient clinic in a pediatric hospital in New Delhi and listened to a father sobbing over the paralysis of his only son. He was a farmer and lived in Uttar Pradesh; counting walks, minibuses and trains, it had taken him 24 hours to get to the hospital. He had carried the toddler the entire way.

His son had gotten the drops, he insisted: Every time the teams came to his neighborhood — which they did three, four times each year — he or his wife had lined up all their children, the boy and his older sisters. His son had had 11, 12 doses, the man said. How could he have gotten polio? And it was polio, the doctor treating him confirmed, not one of the transient febrile paralyses that exist alongside the disease and make detection and diagnosis so complex in resource-poor settings. She saw this all the time, she confided. The massive polio-eradication campaigns that continually blanketed India had trouble reaching some resistant populations, and those children contracted polio because they were not vaccinated — but children whose parents were compliant, who believed in the drops and made sure their children received them, became paralyzed as well.

I was in India that winter because the long-hoped-for goal of the worldwide eradication of polio was supposed to be achieved the following year, in 2000. The global eradication initiative — led by the WHO, the CDC and a massive volunteer effort by Rotary International — didn’t make that goal that year. Or in 2002, or in 2005. For a variety of reasons, from the biology of the disease in the tropics to political manipulation in service of unrelated ends, several countries have remained stubborn hot spots. And as long as the disease persists within their borders, it can leak outside them and become re-established in any area where vaccination has slowed down because the goal of stopping local transmission appears to have been achieved.

Most recently, it has leaked to Tajikistan, a country that has been polio-free since 2002 but shares borders with three of the four countries — India, Pakistan and Afghanistan (Nigeria is the fourth) — where polio remains endemic. As of the last count, 183 children were confirmed to have polio; authorities generally estimate that for every child detected with polio, 200 others may be infected silently and can pass on the disease.

There is so much to say about polio eradication; it is an impossibly complex and expensive task, fraught with cultural complexities and burdened with an endgame of clean-up that will stretch years beyond eradication itself. It is so complex that major public health figures have periodically thrown up their hands and declared eradication unachievable. It is one of the most expensive public health campaigns every attempted, with billions spent so far (and yet chronically short of funds). And because most of the West remains fully vaccinated, polio lurks far below the radar horizon of our concern.

I say all this — which is kind of opening the floodgates for me, because I’ve wanted to talk about polio for years, but it is a damn hard story to sell to editors — because CMAJ, the Canadian Medical Association Journal, has published a great editorial calling for the West to take the threat of polio seriously again.

Although the rates of poliovirus immunization in most of Europe exceed 90%, neither the Ukraine nor Georgia has reached this target. Furthermore, regions of Canada and some European countries have very low rates of vaccine uptake. Infants and toddlers are often not vaccinated on time because of a lack of appreciation of the seriousness of poliomyelitis. Community immunization rates may also be adversely influenced by concerns about vaccine safety, religious beliefs barring vaccination and antivaccine or antigovernment sentiments… There are no cures for poliomyelitis — prevention through vaccination is our best and only defence. We are only one asymptomatic infected traveller away from an outbreak because of low vaccination rates. (MacDonald and Hebert)

Since the year 2000, there have been two recurrences of polio in the US: one in Minnesota, sparked by the vaccine virus, and one in Arizona contracted by a college student traveling abroad. The college student, and the children in the Minnesota community, had never been vaccinated because of religious or cultural exemptions. So our protections are not as impermeable as we think.

This is an addition for archival purposes of a post that originally appeared at Scienceblogs.

The Center for Global Development, a DC think-tank, is releasing what looks like a thoughtful report aimed at refocusing policy debates over drug resistance toward the epidemic’s global impact, with particular attention to the the developing world.

From the report’s preface:

Problems with drug resistance have moved from the patient’s bedside to threaten global public health. Drug resistance has dramatically increased the costs of fighting tuberculosis (TB) and malaria, has slowed gains against childhood dysentery and pneumonia, and threatens to undermine the push to treat people living with HIV/AIDS effectively. Global health funders and development agencies have cause to worry about whether their investments in access to drugs, and global health programming more broadly, are being undone by the relentless advance of drug resistance.

It calls out a sustained lack of leadership:

Past efforts to energize global action to more comprehensively address drug resistance have been sidetracked by poor timing or over-stretched budgets… In an unfortunate coincidence of timing, a WHO Strategy on Antimicrobial Resistance was launched on September 11, 2001. As a result, the action plan prepared for the Strategy did not get carried out, and over time the interest in cross-cutting drug resistance at WHO withered, even while disease-specific attention grew. For many years, the U.S. Government provided support for research, technical support, surveillance, and policy development on drug resistance in developing countries through an annual budget appropriation to the U.S. Agency for International Development (USAID). That support has become narrowed to programming in only a few areas.

It recommends 4 specific steps:

1. Improve surveillance by collecting and sharing resistance information across networks of laboratories
2. Secure the drug supply chain to ensure quality products and practices
3. Strengthen national drug regulatory authorities in developing countries
4. Catalyze research and innovation to speed the development of resistance-fighting technologies

A policy brief is here and the full report is here.

This is an addition for archival purposes of a post that originally appeared at Scienceblogs

Via the Journal of the American Medical Association, a report from Spain: the first recorded outbreak, in a Madrid hospital, of Staphylococcus aureus resistant to linezolid (Zyvox), one of only a few drugs still available to treat very serious infections of drug-resistant staph, MRSA. This is bad news.

Background: The M in MRSA stands for methicillin, the first of the semi-synthetic penicillins, created by Beecham Laboratories in 1960 in response to a worldwide 1950s outbreak of penicillin-resistant staph. The central feature of the chemical structure of both penicillin and methicillin is an arrangement of four atoms, known as the beta-lactam ring, that governs both drugs’ ability to interfere with bacterial cell-wall synthesis. That structure was copied into the formulas of a number of other drug families — the cephalosporins, carbapenems and monobactams — and so MRSA is resistant to them as well. And in addition, the bug has picked up resistance to yet other drug families through horizontal transfer; so increasing the census of new drugs that can treat resistant staph infections is a high priority for drug development. It’s especially critical for severe infections such as ventilator-associated pneumonia, osteomyelitis, endocarditis and bacteremia, since all the remaining last-resort drugs have challenges from toxicities to ineffectiveness in certain organs.

Linezolid is a relatively new drug, out since 2000 (and, as a downside, still under patent and, according to patients who have been prescribed it, very expensive). It was the first of a new drug class, the oxazolidinones; since there were no “me too” similarities to older drugs, clinicians hoped that resistance to linezolid would be slow in coming.

No such luck.

The first recognized case of linezolid resistance in staph was recorded in 2001. Still, there have been relatively few cases of LRSA, or staph that possesses both linezolid and beta-lactam resistance: 8 cases in the US to date, 2 in Germany and 1 each in Brazil, Colombia and the UK.They have all been caused by a particular point mutation, G2576T.

This Spanish outbreak, though, had a different cause, the importation of the cfr gene, which also mediates resistance to the older drugs clindamycin and chloramphenicol, apparently on a plasmid, possibly from a staph strain common in cows. The outbreak caused by this new mechanism was as large as the entire known burden of LRSA to date: 12 patients, over 10 weeks in 2008, in 3 linked ICUs, pls 3 patients who were not in intensive care, but had had previous ICU stays. Six of the patients had ventilator-associated pneumonia and 3 were bacteremic. Six died — though the authors are careful to say that all of these patients were critically ill, with brain tumor and esophageal cancer among other problems, and that LRSA was not directly responsible for all of the deaths.

More bad news: There were actually 4 clones of LRSA within this outbreak, with slightly different resistance patterns. Troublingly, one of the 4 had reduced sensitivity to glycopeptides; the chief glycopeptide is vancomycin, which has been the go-to drug for MRSA for 50 years.

The hospital checked its staff and the ICU environments, and found nothing of significance; there was no reservoir in the hospital that was passing this newly resistant strain to patients. With no obvious solution there, they dialed back sharply on their linezolid use, going from more than 200 doses per day in April 2008 to 25 doses per day in June. That aggressive antibiotic stewardship appears to have put the brakes on the outbreak, and after June, no additional cases were recorded.

An accompanying editorial underlines how critical antibiotic stewardship was in controlling this outbreak, while also pointing out how very liberal the hospital was in prescribing linezolid before the outbreak began — suggesting that if the institution had used its antibiotics more conservatively from the start, this outbreak might not have arisen, or at least not have been as large.

No one doubts the importance of infection-control practices in limiting outbreaks with antibiotic-resistant organisms, but optimizing antibiotic use remains essential for successful control of such outbreaks…No longer can clinicians’ unrestricted use of antibiotics and ignoring suggestions from those who attempt to improve or alter antibiotic use be tolerated. Clinicians must understand the sense of urgency about the appropriate use of antibiotics.

Indeed.

(NB, this outbreak was also written up a few months ago in Clinical Infectious Diseases, and was a late-breaker paper at the 2008 ICAAC meeting.)

This is an addition for archival purposes of a post that originally appeared at Scienceblogs

A couple of days ago, I talked about the link between a potentially massive hepatitis B outbreak in West Virginia and the lack of access to primary dental care. I was mushy qualitatively descriptive, ahem, about the number of people who lack access to dental insurance.

Comes now the CDC to save the day. In a statistical brief posted today, the National Center for Health Statistics gives a concise but thorough overview of the state of dental insurance in the US. Short version: Ain’t pretty.

Crude preliminary population math:

• There are currently 309 million Americans.
• Based on census tables from last summer, 39 million are 65 or older (i.e., eligible for Medicare).
• Based on other census tables from last summer, 52 million are 17 or younger (of which some percentage, based on family income, would be eligible for Medicaid).
• That leaves, with wiggle room, about 218 million working adults.

According to the NCHS:

• 172 million non-elderly Americans have private health insurance. (NB, leaving 46 million non-elderly with no health insurance, which matches the usually accepted figures.)
• Of them, 45 million have no dental coverage — which, added to the 46 million with no insurance at all, means that more than 90 million Americans have no dental coverage at all. (I believe the technical term for a number that large is a crapton. Maybe a metric crapton.)

In addition:

• If you have employer-provided health insurance, your chances of having dental coverage are pretty good: 80%.
• If you have privately purchased insurance of any kind, not so much: 30%.

So, reinforcing Monday’s point: There are multiple millions of Americans who get no assistance paying for dental care, which is a largely cash-only business. (And judging from my own experience — thanks to my childhood in the UK, I have teeth like chalk and consume more than my share of dental care — dental insurance negotiates discounts. So self-pay dental care is relatively more costly.) And therefore, it is not surprising that thousands of people attended that free dental clinic in northeastern West Virginia, and were potentially exposed to hepatitis B as a result.

This is an addition for archival purposes of a post that originally appeared at Scienceblogs.




The Subcommittee on Health of the Energy and Commerce Committee of the House of Representatives has announced a hearing for Wednesday: “Promoting the Development of Antibiotics and Ensuring Judicious Use in Humans.”

The witness line-up is:

• Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, Food and Drug Administration
• Robin Robinson, Ph.D., Director, Biomedical Advanced Research and Development Authority, Department of Health and Human Services
• Brad Spellberg, M.D., F.I.D.S.A., Associate Professor of Medicine, David Geffen School of Medicine at UCLA and Member, Infectious Diseases Society of America Antimicrobial Availability Task Force
• Sandra Fryhofer, M.D., Council on Science and Public Health, American Medical Association
• John S. Bradley, M.D., American Academy of Pediatrics, Chief, Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, School of Medicine, Clinical Director, Division of Infectious Diseases, Rady Children’s Hospital
• Barry Eisenstein, M.D., F.A.C.P., F.I.D.S.A., Senior Vice President, Scientific Affairs, Cubist Pharmaceuticals
• Jeffrey Levi, Ph.D., Executive Director, Trust for America’s Health

This is the second hearing the Health Subcommittee has had this spring, apparently at the prompting of the chairman of Energy and Commerce, Rep. Henry Waxman, who made the opening statement at the first such hearing in April:

We need to debate the health care bill and review its implementation. But we ought to be able to chew gum and walk at the same time. Because it is not going to make much difference if you have health insurance or not if you are going to die from something that could have been prevented from an antibiotic. And we are seeing more and more antibiotic resistance. (Transcript)

Reading between the lines, I’m going to guess this hearing will lean heavily on the IDSA’s campaign to improve market conditions for pharma companies in order to revive antibiotic development (an issue I discussed recently at the old Superbug — we’re working on getting the archives moved over).

This is an addition for archival purposes of a post that originally appeared at Scienceblogs.




Via ProMED Mail comes a news report that about 2,000 people in 5 states are being sought by health departments so they can be checked for hepatitis B infection. The potential source: the Mission of Mercy Dental Clinic, a free dental-care fair held just about a year ago in Berkeley County in the far north-east corner of West Virginia. The potentially infected include 1,137 people who were treated at the two-day clinic and 826 of the volunteers who worked there, from West Virginia, Washington, D.C., Virginia, Maryland, Pennsylvania and North Carolina. Three patients and two volunteers have already been diagnosed. The virus in four of the five matched on molecular fingerprinting, suggesting a common source; the fifth patient refused further testing.

Hepatitis B is blood-borne, so on the surface, this is a story of the tragic consequences of some failure somewhere in the clinic’s infection-control procedures. (One reason why it caught my eye, since I’m interested in healthcare-associated infections.) Except that it’s not — or not only. It’s important to unpick why such an extraordinarily large number of people may have been exposed at one time. Looked at through that lens, it becomes a story about what can happen when we don’t fund basic health care in a timely way.

Some background: West Virginia is one of the poorest states in the country and has some of the highest rates of the usually recognized diseases of poverty: tobacco use, chronic kidney disease, asthma, cardiovascular disease. (Look for West Virginia on these CDC maps of incidence of heart disease and stroke.) But it also has extraordinarily high rates of another health problem that ought to be linked in the public mind to low socioeconomic status, but usually isn’t: untreated dental disease. Eric Eyre of the Charleston Gazette (disclosure: a friend and fellow Kaiser Foundation Fellow) took a year-long close look at dental disease in the state in 2006-07 (slideshow, stories). If you’re squeamish, I advise skipping the one about the woman yanking her own teeth with pliers after a few shots of moonshine.

Dental disease — that’s not just cavities, but tooth loss, bone loss, abscess, Ludwig’s angina, septicemia in the most serious cases — isn’t only a problem for West Virginia, though it happens to be worst there. It’s a problem all over the US because, without ever intending to, we’ve allowed dental care to become a primarily cash-based form of medicine.

If you have a job, you may have dental insurance, though it’s a less-common employment benefit than health insurance, and covers comparatively less of the cost of any procedure. If you don’t have a job, dental care is entirely out of pocket. If you’re poor enough to be on Medicaid, whether or not you have dental coverage depends on which state you live in, because Medicaid dental coverage for adults falls under the portion of Medicaid funded by the states, not the federal government. In the past 12 months, California, Hawaii, Massachusetts, Michigan, Minnesota, North Carolina, and Washington state all cut or tried to cut their contributions to dental Medicaid from their state budgets. If you’re the child of a poor family, you are hypothetically entitled to Medicaid-funded dental care, though that depends on being able to find a local dentist willing to accept Medicaid reimbursement; last year, the Government Accountability Office said that children have trouble finding Medicaid-accepting dentists in 43 out of 50 states.

Net result: Untreated dental disease is now the most common disease of childhood, five times more common than asthma according to a 2000 Surgeon General’s report, and emergency room visits for dental crises are rising steadily. ERs are not the right place to treat dental problems — they don’t fill cavities or do extractions, though they can drain abscesses and give antibiotics and pain meds — but as with so much else in US medicine, ERs offer a mandated clinic of last resort when there’s nowhere else to go. (For more about the interplay between dental care and ER overcrowding, here’s a story I wrote for the June Annals of Emergency Medicine.)

All of that explains why thousands of people from a wide swath of the East Coast were so desperate for free dental care that they were willing to stand in line overnight in a high school parking lot. (The first free dental clinic in West Virginia had to close its doors early after it got 1,100 patients in the first 2 hours.) And also why hundreds of dental-care professionals and students and community volunteers were so eager to help. And why they’re all now waiting by the mailbox, wondering whether they’re in line for a letter that will tell them where to get tested for infection with a life-long chronic disease.

Some of you may have spotted an announcement last week from the Centers for Disease Control and Prevention about a release of data from the National Healthcare Safety Network (NHSN), a repository of hospital infection data. You can guess the big news in the report from its title,  “First State-Specific Healthcare-Associated Infections Summary Data Report”: For the first time, database users are able to calculate healthcare-associated infections (let’s call them HAIs for short) by state, as well as nationally.

Good news, you would think. And it is. According to the CDC’s announcement (press release, press conference transcript), the national rate of one particular type of HAIs, central line associated bloodstream infections or CLABSIs (like it looks — pronounced “klab-sees”) is down 18% from the previous 3 years. Taken together, all HAIs kill at least 100,000 Americans each year (an old number that is probably an underestimate) and cost at least $30 billion per year. CLABSIs are an important component of the spectrum of HAIs and may account for a third of all HAI deaths — so any reduction is a positive development.

And yet: The bigger news about this report, unfortunately, is that it lays bare how little we really know about HAIs, and how little progress has been made in preventing or even documenting them.

Consider:

• The report includes data from only 17 states
• The data does not match state to state, so state rates cannot be compared
• Participation in the NHSN by hospitals is voluntary (except in states that recently have passed mandatory reporting laws) and data is self-reported
• Hospitals that report to the NHSN are not identified (in fact, unless state laws say otherwise, they are guaranteed anonymity)
• The NHSN does not collect data on the most problematic HAI organisms, MRSA and C. difficile.

If you think for a moment about how incomplete this data is, and how much the data collection allows hospitals to avoid saying, then Dr. Peter Pronovost‘s remarks to the Association of Health Care Journalists in April begin to make sense. Pronovost is a MacArthur Fellow for his championship of evidence-based infection prevention, and said (sorry, no verbatim record that I know of, but I live-tweeted his speech) that if hospital infection reporting were truly transparent and truly accountable — right now, it’s neither — the problem of HAIs would end tomorrow, because consumers would be so shocked that they would rise up and demand change.

The CDC says there will be additional data and a new comparison with this first snapshot within about 6 months. Again, that’s all good news. But it’s worth taking a deep look at this report to really understand how little we know — which will also help to explain why this problem so persistently fails to get better.

(NB: The CDC announcement and the relevant background were covered thoughtfully by my friends Dan DeNoon of WebMD and Barbara Feder Ostrov of Reportingonhealth.org, whose post, FWIW, quotes me.)

And, constant readers, an addendum: On Monday, I’ll have big news to share about this blog. It’s good news and I hope you’ll support it. Stay tuned.

Well, constant readers, it’s been an amazing two weeks. SUPERBUG was published, and ate my life. I’ve been on NPR’s Fresh Air, and on 21 (22?) other radio stations so far, with more radio, and TV, to come.

I’m starting to plan the next phase of the book campaign. If you work at a hospital or medical school, or are a student, contact me: Wherever you are, I’ll come talk.

This week I’m headed out for some tour appearances in Atlanta: at Georgia Gwinnett College on Wednesday, and on Thursday, at the offices of Danya International in the afternoon, and then at Eagle Eye Book Shop in Decatur Thursday night. If you need more details, email or tweet me!

The book has gotten some wonderful reviews and, what matters more to me at this point, blog reactions, because the blogs signal to me that real people are really engaging with the story. I’ve put excerpts and links up on the book’s site on this page.

Here’s one that just came in over the transom that just floored me. It’s from Rep. Louise Slaughter, Congress’s only microbiologist, author of PAMTA, the legislation intended to bring some direction and control to agricultural use of antibiotics:

Maryn McKenna’s Superbug provides a heart-rending and enlightening portrait of the spread of Methicillin-Resistant Staphylococcus Aureus (MRSA). Commonly imagined to be a disease that only affects elderly hospital patients, McKenna’s book shows that no area of the United States is untouched. Thirty percent of high school athletic programs in one survey reported MRSA. In another study, 80 percent of farms and 40 percent of pigs had MRSA. The consequences are horrific. In 2005, 94,360 invasive MRSA infections occurred in the United States, with almost 19,000 deaths.

In the United States, the response to MRSA has been largely uncoordinated, and left to individual institutions, schools, and health care centers. American hospitals have tried a range of responses. Some hospitals have tied executive pay to staff hand-washing rates; others isolate patients with MRSA. Nationwide educational campaigns reduced antibiotic prescription rates temporarily, only to see them rise again. The pipeline for new antibiotics dried up due to economic disincentives for drug companies to invest in short-course medications like antibiotics. The medical system has not yet been able to contain antibiotic resistant pathogens like MRSA.

The problem is just as dire on American farms. Limited action has been taken to reduce misuse of antibiotics in agriculture. While the FDA did ban agricultural usage of the powerful antibiotic fluoroquinalone, farms still regularly use powerful antibiotics as ‘growth promoters’ in daily feed for animals.  This year, I introduced legislation, HR 1549, the Preservation of Antibiotics for Medical Treatment Act, which would take additional steps to protect seven medically-critical classes of antibiotics for human usage against MRSA and other antibiotic resistant pathogens. Maryn McKenna’s book is a powerful call to action. 

– Louise M. Slaughter, MEMBER OF CONGRESS

 

Constant readers, huge news: SUPERBUG will be featured in a segment today on the NPR program Fresh Air with Terry Gross. Please tune in if you can! Fresh Air‘s broadcast times vary across the country, but you can listen online or via podcast. The schedule is here.

UPDATE:
Listen to the podcast here.
Read the story here.

OK, folks, mystery unveiled: Here’s what I look and sound like. Simon and Schuster has put up a video for the book — not a trailer, per se, but an interview with me (backed by spooky music!).

I’m having trouble with the embed code – I can’t seem to resize their monster window! — but meanwhile the link is here.

UPDATE: How’s this?

Every year, the CDC sponsors a week-long observance called Get Smart About Antibiotics Week, intended to bring attention to this issue of antibiotic misuse that all of us here are so concerned about, and to link the efforts of federal and state agencies, nonprofit groups, and anyone else with an interest.

Today marks the start of the 2009 week, and of course it comes as a crucial time: With the H1N1 flu pandemic causing so many people to seek care for upper respiratory illnesses, the possibility of antibiotics being misprescribed for a viral illness is greater than usual.

The homepage for the CDC campaign is here. There is an abundant list of materials, images, campaign strategies and suggestions for framing the conversation, along with graphics (I’ve lifted the one at left from a poster aimed at parents of young children), PSA sound files, and cute little web widgets such as the image at right above (sorry for the poor layout skills, it’s a busy morning).

Since this comes from the CDC and is therefore taxpayer-funded, all of it is open-access. So go, already.

I know that many of you who are MRSA patients, especially with recurrent infections, are especially interested in the issue of decolonization, the grueling regimen of antibiotic nasal gel (containing mupirocin; usually sold as Bactroban) combined with body washes with chlorhexidine (Hibiclens) that is believed to eradicate MRSA carriage in the nose and on the skin. Decolonization is an essential part of the “search and destroy” measures practiced by zero-tolerance hospitals who want to detect any MRSA transport in their institution, and it is a last-ditch hope in recurrent community-strain infections. (I told the story of several women’s struggles with recurrent infections in SELF and Health magazines.)

It’s disheartening, then, to realize that decolonization is not a universally agreed-upon measure, and there is relatively little research that can say in which setting (household, hospital, ICU) it works best, and why. There have been a few studies, and a few review papers summing up studies, on the role that decolonization can play in reducing the risk of infection in already hospitalized, colonized patients — ones about to undergo surgery, for instance. A meta-analysis by the Cochrane group, of 8 trials, found that decolonization in the hospital did reduce the likelihood of infections in surgical patients.

The role that decolonization can play in short-circuiting community infections is much less clear, though there are many, many people who have suffered recurrent infections and testify that it worked for them. (Please speak up in the comments if you are!) One problem is that outside hospitals, there is no one recommended regimen: One physician might tell her patient to use mupirocin and chlorhexdine only, whereas another might tell his patient to also take bleach baths, or bleach all the laundry or household surfaces. The CDC has so far declined to put its muscle behind decolonization in community-strain infections, recommending only that frustrated patients with recurrences seek the advice of an infectious-disease specialist. (See this flowchart of treatment options (.pdf) that the CDC published in 2007.)

Comes now the infectious-diseases division of Evanston Northwestern Healthcare, whom some of you will recognize as being among the most successful and evangelical practitioners of “search and destroy” in the United States. (ENW has recently been renamed NorthShore University HealthSystem and is affiliated with Northwestern University. Disclosure, in case you care: I went to grad school at Northwestern, though not in medicine.) In a paper published in Infection Control and Hospital Epidemiology, the group evaluates the use and success rate of decolonization in ENW/NorthShore’s 3 hospitals and finds, well, not such good news: a temporary reduction in patients’ being colonized with MRSA, but no success in preventing infection.

This is an important and troubling finding, because decolonization comes with costs. There is the obvious cost to hospitals (and the follow-on cost to insurance companies and consumers) of paying for mupirocin and chlorhexidine themselves. But there is also a hidden cost that we here should be particularly sensitive to: Because mupirocin is being used so lavishly, mupirocin resistance is rising.

In the same issue of ICHE (which, yes, is pronounced Itchy), a related editorial by Dutch researchers reviews the difficulty of conducting decolonization trials, but summarizes the ENW/NorthShore study as not an endorsement of decolonization regimens:

It is clear that staphylococcal carriage is an important risk factor for infection and that eradication of carriage has proven successful for patients who are undergoing elective surgery. For other groups of patients, it is still unclear what the benefits are. It is obvious that indiscriminate use of mupirocin is associated with development of resistance. Therefore, additional studies are warranted to define the optimal MRSA decolonization strategy, including what should be given, to whom, and at what moment and who should guide and supervise the regimen.

The cites are:
Robicsek A, Beaumont JL, Thomson RB Jr et al. Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk. Infect Control Hosp Epidemiol. 2009 Jul;30(7):623-32.
Kluytmans J, Harbarth S. Methicillin-resistant Staphylococcus aureus decolonization: “Yes, we can,” but will it help? Infect Control Hosp Epidemiol. 2009 Jul;30(7):633-5.

Constant readers, some of you may be aware that one major nexus of MRSA infection gets very little attention, though I’ve tried to raise it here periodically. That’s MRSA in jails and prisons: Thanks to poor hygiene and extraordinary overcrowding, jails and prisons are hotbeds of the bug, and it is very common for people to develop an infection after they are incarcerated, and then to be unable to shake it because they cannot keep up with hygiene, cannot get access to a doctor, etc.

Some commenters, here and elsewhere online, have suggested that this is no more than prisoners deserve. This seems to me both extraordinarily uncompassionate and epidemiologically foolish. In case no one has noticed, prison overcrowding is so serious that many prisoners don’t stay in prison for their sentenced time. And when they come out, and come back to their communities, they bring MRSA with them. That’s not even to mention the risk to the very large numbers of people who are not themselves incarcerated, but go in and out of jails and prisons every day: correctional officers, cooks, medical staff, and on and on.

All of which makes the news from California on Friday more than usually depressing.

Prison medical care in California has been so bad (see Gov. Arnold Schwarzenegger’s 2006 emergency declaration) that it is no longer under control of the state, but rather administered by a court-appointed receiver, who said in 2007:

Across the board we see delays in diagnosis and access to care and needed tests; misfiled, incomplete or illegible medical records; lack of space, sanitation and staffing; botched hand-offs of medical information during inmate transfers; failures by clinicians to recognize and evaluate “red flag” symptoms, follow published guidelines, perform basic physical examinations or respond to patient complaints; abdication of responsibility for patient care and lack of critical thinking or requests for help in difficult cases.

The prevalence of MRSA in California prisons is an important part of that picture : Correctional officers have sued over MRSA they acquired at work. (And yes, you can read all about it in SUPERBUG.)

Now, you may also know that California is in the midst of a gruesome budget crunch — and on Friday, the push for better prison medical care and the deficit in the state budget collided, and the deficit won. According to the Associated Press and the San Francisco Chronicle, the Schwarzenegger administration backed off an agreed-upon plan that would have ended the receivership and returned control of the medical system to the state at a cost of $1.9 billion, one-fourth of what was originally thought to be needed.

Schwarzenegger said in a statement Thursday that California cannot afford the additional cost.
“We cannot agree to spend $2 billion on state-of-the-art medical facilities for prisoners while we are cutting billions of dollars from schools and health care programs for children and seniors,” he said.
Schwarzenegger and lawmakers are considering eliminating or significantly reducing education, state parks and core social programs to address the $24.3 billion budget shortfall. (AP, byline Don Thompson)

The Chronicle story makes clear that the prison spending would not have made the deficit any worse, because the money was coming from new bonds, not from the state’s general fund. Its online commenters don’t seem to have paid attention to that, as they hit the same familiar themes:

• “Why should the public have to babysit them for the medical problems they brought on themselves… Let them rot.”
• “In my opinion bad medical services in prison should be only one of the deterrents that keeps one from wanting to go to jail. “
• “Prison should be a place that is so intolerable, that no sane person would ever want to go there.“

It’s easy to moralize. It’s much harder, as we know here, to control the continuing spread of a microbe that has already gotten a solid foothold in the community. California’s decision to not improve medical care in its prisons — and therefore not address the threat of MRSA to its prisoners and staff — is practically a guarantee that the state’s already substantial community MRSA problem is going to get much worse.

Constant readers: Funny how one loses track. According to the dashboard, this is my 200th post at SUPERBUG. I’m thrilled and humbled that we’ve been able to build this solid community in support of more attention to this very under-appreciated disease. You are the ones that make it happen, and I am very grateful.

It was news to me, until a friend of mine went and bought it: My first book, Beating Back the Devil: On the Front Lines with the Disease Detectives of the Epidemic Intelligence Service, has been put into a Kindle edition.

BBtD was the first and so far only book to go inside the CDC’s “outbreak police.” It tells a year in the life of the first class of young physicians and PhDs to join the Epidemic Intelligence Service after the anthrax attacks — the first year, in other words, in which the EIS officers knew in advance that the possibility of confronting bioterrorism was no longer hypothetical. It tracks members of the class around the planet, from West Nile virus to foodborne illness to malaria prevention in Malawi to SARS. In alternating chapters, it also tells the hidden history of the EIS, which was founded in 1951 as a post-Korean War force for bioterror detection. Its members were in on every major disease event of the second half of the 20th century: the launch and near-failure of the polio vaccine, the end of smallpox, the beginning of AIDS, and the emergency investigation of the anthrax attacks (during which I was embedded with a CDC team).

Most important for our purposes here, BBtD takes you inside an investigation of a MRSA outbreak — in Los Angeles in 2003, when gay men who frequented sex clubs began developing cripplingly serious skin infections, and a young CDC investigator had to determine whether to call on the city to shut the clubs down…

Constant readers – lots of new news happening, and blogposts coming. While I organize it, here’s a strip from one of my favorite webcomics, XKCD.com.

If you have young teens or younger, here’s a fun resource aimed at persuading them to wash their hands. (And if you don’t, it might tune you up to pre-teen culture):

Mitchel Musso, who plays the boy best friend on the Disney TV Show Hannah Montana, has filmed a public service announcement TV spot: “Clean Hands Are Cool Hands.”

It’s part of a campaign sponsored by the Hospital Corporation of America (HCA) and Steris Corp., which makes infection-control and surgical gear. The kid side of the site has behind-the-scenes cuteness — music, photos, video outtakes; the parent/teacher side, medical information, lesson plans, posters and stickers.

Can’t hurt. May help. Cute.